Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03327272

Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Rush University Medical Center · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Neural injury is a well-known complication following extreme lateral lumbar interbody fusion (XLIF). It has been found that up to 9.4% of patients will have either temporary or persistent neurologic deficit. This occurs with traversal of the psoas muscle or direct injury to lumbosacral plexus or sympathetic ganglion. While often temporary, it can cause hip flexor weakness, thigh numbness, or pain. Several studies have demonstrated reduced patient reported pain scores following steroid administration, particularly in the early postoperative period. However, few studies have investigated the efficacy of intraoperative local injection of corticosteroid in reducing the incidence and duration of postoperative pain or neurologic injury for XLIF patients.

Detailed description

The purpose of this study is to determine if the incidence and duration of postoperative pain is reduced in the subjects receiving a local injection of methylprednisolone when compared to placebo following XLIF. The investigators hypothesize that subjects undergoing XLIF who receive local methylprednisolone will have: 1. Reduced incidence and duration of postoperative pain and neurologic injury 2. Shorter hospital stay 3. Better short- and long-term outcomes The study also aims to answer the following questions: 1. Do subjects who receive local corticosteroids have a reduced incidence and duration of postoperative pain and neurologic deficit compared to those who receive placebo? 2. Do subjects who receive local corticosteroids have a reduced hospital stay compared to those who received placebo? 3. Is local corticosteroid therapy associated with improved short and long-term outcomes?

Conditions

Interventions

TypeNameDescription
DRUGMethylprednisoloneInjection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
DRUGSalineAdministration of saline at surgical site prior to incision closure

Timeline

Start date
2018-05-22
Primary completion
2020-07-24
Completion
2020-07-24
First posted
2017-10-31
Last updated
2020-11-20

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03327272. Inclusion in this directory is not an endorsement.